Von Willebrand disease 3
MONDO:0010191Type 3 von Willebrand disease (type 3 VWD) is the most severe form of VWD characterized by a bleeding disorder associated with a total or near-total absence of Willebrand factor (von Willebrand factor; VWF) in the plasma and cellular compartments, also leading to a profound deficiency of plasmatic factor VIII (FVIII).
Also known as: VWD3, von Willebrand disease 3, von Willebrand disease type 3, von Willebrand's disease 3, von Willebrand's disease type 3, VON WILLEBRAND disease, type 3, VWD, type 3, Von Willebrand disease, type 3
22 clinical trials for this condition and its sub-types, 9 tagged with Von Willebrand disease 3 itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Trial for bleeding disorder drug in toddlers pulled before it started
Disease control CancelledThis study was designed to test how FANHDI, a clotting factor concentrate, works in children under 6 with severe von Willebrand disease (types 2 or 3). The goal was to measure how the drug moves through the body and how well it controls bleeding. However, the trial was withdrawn …
Phase 4 • Sponsor: Grifols Therapeutics LLC • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Newborn screening study aims to catch rare diseases at birth
Diagnosis OngoingThis study offers voluntary screening for newborns in North Carolina to detect a wide range of rare health conditions early. Using a small blood sample already collected at birth, the program tests for dozens of disorders, including spinal muscular atrophy, cystic fibrosis, and m…
Sponsor: RTI International • Aim: Diagnosis
Last updated Jul 03, 2026 00:00 UTC
-
Real-World study tracks bleeding and daily life in rare bleeding disorder
Knowledge-focused OngoingThis study observes 44 people with type 3 von Willebrand disease, a rare bleeding disorder, who are already on standard preventive treatment. Researchers will track how often bleeding episodes occur and how the condition affects quality of life over at least 24 weeks. No new drug…
Sponsor: Hoffmann-La Roche • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC